Frederick T. Muto - 01 Jul 2022 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Reporting relationship: Director
Issuer ticker: IONS
Reported as of: 01 Jul 2022
Net transaction value: +$145,575
SEC form: 4
Accepted by SEC: 06 Jul 2022, 17:25:53 UTC
Prior SEC filing: 19 Jul 2021
Next SEC filing: 19 Jul 2022
Source filing: View source filing
Reporting owner signature: By: Patrick R. O'Neil, attorney-in-fact For: Frederick T. Muto

Key filing fact

Frederick T. Muto filed Form 4 for IONIS PHARMACEUTICALS INC (IONS) on 06 Jul 2022.

Key facts

This page summarizes Frederick T. Muto's Form 4 filing for IONIS PHARMACEUTICALS INC (IONS).
4 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 06 Jul 2022, 17:25.

Change

Previous filing in this sequence was filed on 19 Jul 2021.
Current net transaction value: +$145,575.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IONS transaction

Common Stock

Options Exercise

Transaction value: $145,575
Shares: +11,250
Change %: +28%
Price: $12.94
Shares after: 51,599
Date: 01 Jul 2022
Ownership: Direct
Footnotes: F1

IONS holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,500
Date: 01 Jul 2022
Ownership: By Cooley Pen Plan

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IONS transaction Derivative

Non-Qualified Stock Option (right to buy)

Options Exercise

Transaction value: $0
Shares: -11,250
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 01 Jul 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 11,250
Exercise price: $12.94

IONS transaction Derivative

Non-Qualified Stock Option (right to buy)

Award

Transaction value: $0
Shares: +12,000
Change %
Price: $0.000000
Shares after: 12,000
Date: 01 Jul 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,000
Exercise price: $38.06
Footnotes: F2

IONS transaction Derivative

Restricted Stock Unit

Award

Transaction value: $0
Shares: +5,333
Change %: +55%
Price: $0.000000
Shares after: 15,108
Date: 01 Jul 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,333
Exercise price: $0.000000
Footnotes: F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Acquired as a result of exercising a stock option that was scheduled to expire on 7/1/2022.

Footnote F2

Grant on July 1, 2022 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2022.

Footnote F3

Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

Footnote F4

Grant on July 1, 2022 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2022.